Janux Therapeutics reported a net margin of -214.01% for the quarter ended Jun 2026. These financial ratios cover 23 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||
| EBT Margin | -928.90% | -830.20% | -843.93% | -714.08% | -920.90% | -564.67% | -852.49% | -1,656.39% | -459.59% | -477.77% | -1,178.91% | -66.98% | -6,391.57% | -243.13% | -652.59% | -214.01% | |||||||
| EBIT Margin | -940.72% | -834.78% | -852.23% | -729.85% | -994.04% | -642.04% | -990.28% | -1,962.91% | -628.25% | -655.71% | -1,610.30% | -155.36% | -8,164.46% | -352.51% | -916.50% | -308.66% | |||||||
| EBITDA Margin | -940.72% | -834.78% | -852.23% | -729.85% | -994.04% | -642.04% | -990.28% | -1,962.91% | -628.25% | -655.71% | -1,610.30% | -155.36% | -8,164.46% | -352.51% | -916.50% | -308.66% | |||||||
| Operating Margin | -940.72% | -834.78% | -852.23% | -729.85% | -994.04% | -642.04% | -990.28% | -1,962.91% | -628.25% | -655.71% | -1,610.30% | -155.36% | -8,164.46% | -352.51% | -916.50% | -308.66% | |||||||
| Net Margin | -928.90% | -830.20% | -843.93% | -714.08% | -920.90% | -564.67% | -852.49% | -1,656.39% | -459.59% | -477.77% | -1,178.91% | -66.98% | -6,391.57% | -243.13% | -652.59% | -214.01% | |||||||
| FCF Margin | -558.67% | -687.50% | -786.22% | -294.76% | -878.87% | -491.00% | -698.54% | -1,485.53% | -476.80% | -423.24% | -1,200.80% | -113.70% | -513.90% | -129.49% | -366.27% | 129.98% | |||||||
| Efficiency | |||||||||||||||||||||||
| Assets AverageAssets Avg. | 393.95M | 385.45M | 374.21M | 376.98M | 380.56M | 369.88M | 358.48M | 347.23M | 364.18M | 383.63M | 534.70M | 690.20M | 693.22M | 878.27M | 1,056.14M | 1,041.49M | 1,028.49M | 1,013.17M | 1,014.89M | 1,017.94M | |||
| Asset Utilization RatioAsset Util. | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | |||
| Leverage & Solvency | |||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | |||||||||||||||||||||||
| Times Interest Earned | |||||||||||||||||||||||
| Valuation | |||||||||||||||||||||||
| Price to EarningsP/E | -82.72 | -34.60 | -44.26 | -30.01 | -33.70 | -34.12 | -28.97 | -28.39 | -40.21 | -42.21 | -132.24 | -366.68 | -84.74 | -156.43 | -67.96 | -40.46 | -60.44 | -26.08 | -34.73 | -42.70 | |||
| Price to SalesP/S | 768.38 | 287.28 | 373.56 | 214.26 | 310.31 | 192.65 | 246.98 | 470.17 | 184.83 | 201.66 | 0.00M | 245.60 | 0.01M | 146.94 | 226.64 | 91.38 | |||||||
| Price to BookP/B | 2.36 | 1.27 | 1.67 | 1.47 | 1.70 | 1.71 | 1.63 | 1.66 | 1.33 | 1.44 | 2.98 | 3.32 | 3.62 | 3.09 | 1.58 | 1.38 | 1.50 | 0.87 | 0.90 | 1.01 | |||
| Enterprise Value | 194.31M | 89.29M | 232.39M | 152.43M | 223.84M | 221.07M | 188.94M | 193.68M | 115.49M | 152.26M | 1,300.03M | 1,538.78M | 1,719.65M | 2,137.15M | 583.40M | 373.77M | 480.43M | -133.26M | -110.36M | -32.76M | |||
| EV to EBIT | -17.82 | -6.62 | -17.16 | -8.83 | -12.42 | -12.10 | -9.32 | -9.33 | -7.30 | -9.44 | -64.48 | -111.33 | -47.98 | -73.64 | -16.72 | -8.28 | -13.63 | 3.14 | 3.23 | 1.03 | |||
| EV to EBITDA | -17.82 | -6.62 | -17.16 | -8.83 | -12.42 | -12.10 | -9.32 | -9.33 | -7.30 | -9.44 | -64.48 | -111.33 | -47.98 | -73.64 | -16.72 | -8.28 | -13.63 | 3.14 | 3.23 | 1.03 | |||
| Market Capitalization | 890.55M | 464.25M | 593.59M | 506.73M | 562.60M | 548.09M | 505.81M | 496.97M | 465.21M | 496.29M | 1,951.80M | 2,185.08M | 2,377.68M | 3,162.32M | 1,597.55M | 1,369.78M | 1,469.42M | 833.30M | 846.03M | 938.16M | |||
| Price to FCFP/FCF | -137.54 | -41.79 | -47.51 | -72.69 | -35.31 | -39.24 | -35.36 | -31.65 | -38.76 | -47.65 | -129.83 | -216.00 | -0.00M | -188.42 | -91.84 | -56.40 | -113.48 | -29.09 | -61.88 | 70.30 | |||
| EV to FCF | -30.01 | -8.04 | -18.60 | -21.87 | -14.05 | -15.83 | -13.21 | -12.33 | -9.62 | -14.62 | -86.47 | -152.11 | -762.26 | -127.34 | -33.54 | -15.39 | -37.10 | 4.65 | 8.07 | -2.45 | |||
| EV to CFO | -33.19 | -8.52 | -20.17 | -25.10 | -16.69 | -18.56 | -13.58 | -12.87 | -9.86 | -15.38 | -87.62 | -153.56 | -770.80 | -127.78 | -34.27 | -15.70 | -37.37 | 4.67 | 8.95 | -2.62 | |||
| Return Ratios | |||||||||||||||||||||||
| Return on Sales [ROS]ROS | -940.72% | -834.78% | -852.23% | -729.85% | -994.04% | -642.04% | -990.28% | -1,962.91% | -628.25% | -655.71% | -1,610.30% | -155.36% | -8,164.46% | -933.58% | -1,216.61% | -33,002.05% | -352.51% | -1,576.67% | -916.50% | -308.66% | |||
| Return on Capital Employed [ROCE]ROCE | -5.53% | -8.84% | -12.22% | -15.16% | -17.11% | -18.99% | -21.56% | -23.48% | -21.48% | -19.69% | -13.90% | -9.72% | -12.72% | -11.48% | -10.94% | -14.20% | -14.42% | -15.96% | -16.42% | -14.99% | |||
| Return on Assets [ROA]ROA | -5.31% | -8.48% | -11.70% | -14.45% | -15.87% | -17.05% | -18.72% | -19.51% | -17.19% | -15.20% | -10.40% | -6.38% | -8.73% | -7.86% | -7.36% | -10.14% | -9.91% | -11.21% | -11.28% | -10.08% |